Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 433 across all filing types
Latest filing 2025-07-28 AGM Information
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed communication about the proceedings of the 24th Annual General Meeting (AGM) of Windlas Biotech Limited held on July 28, 2025. It includes information about attendance, resolutions passed, voting procedures, and mentions the presence of auditors and committees. The content focuses on the AGM event itself rather than the full annual report or financial statements. The document is over 5,000 characters and contains substantive details about the AGM proceedings, which aligns with the category for AGM Information (AGM-R). It is not merely an announcement or a brief notice, nor is it a full annual report or financial statement. Therefore, the correct classification is AGM Information (AGM-R).
2025-07-28 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges regarding a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended June 30, 2025. It mentions enclosing a certificate from the Registrar and Share Transfer Agent but does not contain any financial data or detailed report content. The length is only 1469 characters, indicating it is a brief regulatory communication rather than a full report. It fits the criteria for a Regulatory Filing (RNS) as it is a compliance-related certificate submission without substantive financial or operational data.
2025-07-09 English
General Updates
Report Publication Announcement Classification · 95% confidence The document is a letter from Windlas Biotech Limited dated July 6, 2025, addressed to the stock exchanges (BSE and NSE). It announces the publication of newspaper advertisements regarding the completion of dispatch of the Notice of the 24th Annual General Meeting and the Annual Report for the financial year 2024-2025. The letter references compliance with SEBI Listing Regulations and the Companies Act, indicating regulatory compliance and notification. The document does not contain the Annual Report itself but announces that the Annual Report and Notice have been sent to members and are available on the company's website. The document length is 15,000 characters, but the content is primarily an announcement of dispatch and availability of the Annual Report, not the report itself. According to the "Menu vs Meal" rule, such a document is classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K).
2025-07-06 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed notice of the 24th Annual General Meeting (AGM) of Windlas Biotech Limited. It includes the date and time of the AGM, the agenda items such as adoption of audited financial statements for the fiscal year ended March 31, 2025, declaration of dividend, appointment of directors and auditors, and approval of remuneration and stock plans. The document is addressed to stock exchanges and shareholders, and it complies with regulatory requirements for AGM notices under SEBI and Companies Act regulations. It does not contain the actual financial statements or detailed financial analysis but rather the notice and agenda for the AGM. Therefore, this document is best classified as AGM Information (AGM-R).
2025-07-05 English
Record Date
AGM Information Classification · 95% confidence The document is a formal letter from Windlas Biotech Limited addressed to stock exchanges regarding the intimation of the 24th Annual General Meeting (AGM) and the record date for dividend eligibility. It mentions the date and mode of the AGM, the record date for dividend, and the dividend amount recommended by the Board, subject to shareholder approval at the AGM. The document does not contain any financial statements or detailed financial data, nor is it a transcript or report. It is an announcement related to the AGM and dividend record date, which fits the category of AGM Information (AGM-R). The document length is short (1894 characters), and it is clearly an announcement rather than a full report or financial filing.
2025-07-05 English
General Updates
Regulatory Filings
2025-07-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.